Cancer Risks in Thyroid Cancer Patients
Author Information
Author(s): P. Hall, L.-E. Holm, G. Lundell, G. Bjelkengren, L.-G. Larsson, S. Lindberg, J. Tennvall, H. Wicklund, J.D. Boice Jr
Primary Institution: Karolinska Hospital
Hypothesis
What is the risk of second primary cancer in thyroid cancer patients treated with iodine-131 compared to those not treated?
Conclusion
Thyroid cancer patients treated with iodine-131 have an increased risk of certain secondary cancers, but the overall risk does not significantly change over time.
Supporting Evidence
- 99 second primary cancers were observed in the iodine-131 group.
- The standardized incidence ratio (SIR) for the iodine-131 group was 1.43.
- Significantly elevated risks were noted for salivary glands, kidney, and adrenal gland cancers in the iodine-131 group.
- No elevated risk of subsequent breast cancer or leukaemia was noted in the iodine-131 group.
- Patients receiving higher doses of iodine-131 had a higher overall risk of secondary cancers.
Takeaway
This study looked at thyroid cancer patients to see if those treated with a specific radioactive treatment had a higher chance of getting other cancers. It found some increased risks but not for all types of cancer.
Methodology
The study analyzed data from 834 thyroid cancer patients treated with iodine-131 and 1,121 patients treated by other means, using record-linkage with the Swedish Cancer Register.
Potential Biases
Increased surveillance may have led to the detection of cancers that would not have been clinically apparent.
Limitations
The study had a relatively small number of patients and potential selection biases.
Participant Demographics
74% females and 26% males in the iodine-131 group; 76% females and 24% males in the non-treated group.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.17-1.75
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website